Skip to content

Tamiflu maker negotiating with other companies to increase production

WASHINGTON Copyright 2005 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed. ? Roche Holding AG appears to be close to finalizing a deal with 15 drug producers that would dramatically increase the world’s supply of Tamiflu in preparation for a possible flu pandemic.

Sen. Charles Schumer, D-N.Y., said Thursday that agreement had been reached. Roche would only confirm that it is in “advanced discussions” with potential partners.

“No final agreement has been reached,” said company spokesman Terence Hurley.

Mylan Laboratories, a major producer of generic medications, used the same language to describe the talks.

Tamiflu is in great demand in many parts of the world because of the fear of bird flu, a form of influenza that has been contracted by about 120 humans who have had close contact with infected poultry. Tamiflu can reduce the severity of the disease if taken early enough.

Schumer said Teva Pharmaceuticals and Mylan Laboratories are among 15 companies that will work with Roche to increase supply. Hurley confirmed the names of the two companies as part of the negotiations, but would only say, “Please understand that as these talks are ongoing we cannot confirm additional individual companies at this point.”

Roche has received inquiries from more than 200 companies and governments expressing an interest in helping with some or all of the manufacture of Tamiflu. Roche is currently assessing these approaches, and the company said its negotiations would focus on those companies that are likely to have the technical skills required to manufacture the drug.

The company also has written to the governments of Thailand, Philippines and Indonesia to tell them that Tamiflu is not patent protected in their country. As a result, those governments are free to manufacture Tamiflu at their discretion and without paying compensation to Roche.

“Roche has made the right decision,” Schumer said. “Instead of closely holding their patent rights and production techniques, in the face of a global health risk, they’ve moved swiftly to partner with multiple companies to dramatically increase production of this potentially lifesaving drug.”

Roche said it will increase production of Tamiflu to treat 300 million people annually by 2007. The U.S., which has not seen any signs of the bird flu ? known as H5N1 virus ? in birds or people, has only enough doses now for 4.3 million people. President Bush has proposed stockpiling enough Tamiflu and Relenza, another antiviral medication, for 81 million people.

The regular flu kills about 36,000 people a year in the United States, but health authorities fear bird flu would be much more lethal if it ever mutated to the point where it is transmitted from person to person. People have no natural immunity to the virus.

A Mylan Labs official said the company was ready to work with Roche if needed.

“We haven’t yet finalized an agreement, but as we previously announced, we are prepared to produce significant volumes of Tamiflu in support of this potential global health crisis,” said company spokesman Patrick Fitzgerald.

‘

On the Net:

Bird flu: http://www.pandemicflu.gov

Leave a Comment